Frequently Asked Questions

What does ETHIC stand for?

Early thromboprophylaxis in COVID-19

What is ETHIC?

ETHIC is an open-label randomized controlled trial of community-based prophylactic enoxaparin versus standard of care. To break that down further:

  • Enoxaparin is used to treat or prevent a type of blood clot called deep vein thrombosis

  • Open-label: a trial in which information is not withheld from participants

  • Randomized control trial: patients are allocated at random to receive one of several clinical interventions

  • Standard of care: a diagnostic and treatment process that a clinician should follow for a certain type of patient, illness, or clinical circumstance.

So ETHIC will compare outcomes between a set of patients who are treated with enoxaparin and patients who are treated as normal.

How many patients are being enrolled?

Approximately 1,370 patients, with 685 randomly assigned to receive enoxaparin

Where will this trial take place?

ETHIC involves patients in community-based settings from 10 countries: UK, France, Italy, South Africa, Brazil, Australia, Singapore, Thailand, Spain

How will the study work?

The representative site in your country will log all patients invited to participate. 
You will be required to provide written informed consent before any trial related procedures.

685 participants will be randomly assigned to be treated with enoxaparin. The remaining participants will receive standard care and act as the control group. Data will be collected from you at the beginning and after and 30 days, and at 3 and 6 months in cases of hospitalization and other unplanned clinical events.
 

 


 

© 2020 by Thrombosis Research Institute